Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
generic:
mechanism:
5-HT2A agonist (26) ·
Monoamine releasing agent (9) ·
GABAA positive allosteric modulator (8) ·
CB1/CB2 agonist (7) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
Potent 5-HT2A agonist (5) ·
LSD analogue; 5-HT2A agonist (4) ·
Prodrug of LSD; 5-HT2A agonist (4) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
None (2) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Contains LSA (2) ·
Contains mescaline (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
NMDA antagonist (2) ·
Prodrug of GHB (2)
None (154) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) ·
Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1)
None (154) ·
42 mg PO once daily with food (no titration) (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) ·
Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) ·
Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)
None (154) ·
Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
~18 hours (terminal) (1) ·
~91 hours (1)
None (154) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Limited data (1) ·
Limited data; National Pregnancy Registry available (1) ·
Limited data; National Pregnancy Registry for Atypical Antipsychotics (1)
Showing below up to 158 results in range #1 to #158.
1
2
- 2-AI
- 2-FA
- 2-FDCK
- 2-FMA
- 25B-NBOH
- 25B-NBOMe
- 25C-NBOH
- 25C-NBOMe
- 25I-NBOH
- 25I-NBOMe
- 25N-NBOMe
- 2C-B-FLY
- 2C-C
- 2C-D
- 2C-E
- 2C-I
- 2C-P
- 2C-T-2
- 2C-T-7
3
4
- 4-AcO-DET
- 4-AcO-DiPT
- 4-AcO-DMT
- 4-AcO-MET
- 4-AcO-MiPT
- 4-FA
- 4-FMA
- 4-HO-DET
- 4-HO-DiPT
- 4-HO-DPT
- 4-HO-EPT
- 4-HO-MET
- 4-HO-MiPT
- 4-MeO-PCP
- 4F-EPH
- 4F-MPH
5
7
A
- AB-FUBINACA
- Acacia confusa
- Acetylfentanyl
- AL-LAD
- ALD-52
- Allylescaline
- Alpha-PHP
- Alpha-PVP
- Amanita muscaria
- AMT
- APICA
- Ayahuasca
B
C
D
E
F
G
H
I
J
K
L
M
- MCPP
- MDPV
- Mephedrone
- MET
- Methallylescaline
- Methcathinone
- Methoxetamine
- Methylnaphthidate
- Methylone
- Metizolam
- Mexedrone
- MiPLA
- MiPT
- Mitragynine
- Morning Glory
- Myristicin


